G. Deng, B. Cassileth, L. Cohen, J. Gubili, P. Johnstone, Nagi B. Kumar, A. Vickers, D. Abrams, D. Rosenthal, S. Sagar, D. Tripathy
{"title":"Integrative Oncology Practice Guidelines.","authors":"G. Deng, B. Cassileth, L. Cohen, J. Gubili, P. Johnstone, Nagi B. Kumar, A. Vickers, D. Abrams, D. Rosenthal, S. Sagar, D. Tripathy","doi":"10.2310/7200.2007.002","DOIUrl":"https://doi.org/10.2310/7200.2007.002","url":null,"abstract":"Integrative Oncology Practice Guidelines Yuan-Sheng Liu, Jong-Hoon Lee, Yeon-Weol Lee, Chong-Kwan Cho, Hwa-Seung Yoo East-West Cancer Center, College of Oriental Medicine, Daejeon University The Society for Integrative Oncology (SIO) is an international organization established to encourage scientific evaluation, dissemination of evidence-based information, and appropriate clinical integration of complementary therapies (http://www.Integrativeonc.org.). Practice Guidelines were developed by the authors listed below and by the Executive Committee of the Society for Integrative Oncology, which approved this document. Guidelines are a work in progress; they will be updated as needed and are available on the SIO Web site as well: www.IntegrativeOnc.org.","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 2 1","pages":"65-84"},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68604391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Weidong Lu, David Hu, Elizabeth Dean-Clower, Anne Doherty-Gilman, Anna T R Legedza, Hang Lee, Ursula Matulonis, David S Rosenthal
{"title":"Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trials.","authors":"Weidong Lu, David Hu, Elizabeth Dean-Clower, Anne Doherty-Gilman, Anna T R Legedza, Hang Lee, Ursula Matulonis, David S Rosenthal","doi":"10.2310/7200.2006.035","DOIUrl":"https://doi.org/10.2310/7200.2006.035","url":null,"abstract":"<p><p>Chemotherapy-induced leukopenia and neutropenia are common side effects during cancer treatment. Acupuncture has been reported as an adjunct therapy for this complication. The current study reviewed published randomized controlled trials of acupuncture's effect and explored the acupuncture parameters used in these trials. We searched biomedical databases in English and Chinese from 1979 to 2004. The study populations were cancer patients who were undergoing or had just completed chemotherapy or chemoradiotherapy, randomized to either acupuncture therapy or usual care. The methodologic quality of trials was assessed. From 33 reviewed articles, 682 patients from 11 eligible trials were included in analyses. All trials were published in non-PubMed journals from China. The methodologic quality of these trials was considerably poor. The median sample size of each comparison group was 45, and the median trial duration was 21 days. The frequency of acupuncture treatment was once a day, with a median of 16 sessions in each trial. In the seven trials in which white blood cell (WBC) counts were available, acupuncture use was associated with an increase in leukocytes in patients during chemotherapy or chemoradiotherapy, with a weighted mean difference of 1,221 WBC/muL on average (95% confidence interval 636-1,807; p < .0001). Acupuncture for chemotherapy-induced leukopenia is an intriguing clinical question. However, the inferior quality and publication bias present in these studies may lead to a false-positive estimation. Meta-analysis based on these published trials should be treated in an exploratory nature only.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26561051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Training massage therapists to work in oncology.","authors":"Wendy Miner","doi":"10.2310/7200.2007.015","DOIUrl":"https://doi.org/10.2310/7200.2007.015","url":null,"abstract":"<p><p>Professional massage therapists (MTs) require specialized training to work safely and effectively with cancer patients and to prepare them for their role in multidisciplinary clinical settings. This article describes \"Medical Massage for the Cancer Patient,\" a certificate course offered to achieve those goals by the Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center. MTs are taught the clinical, logistic, and legal requirements; the basic details of cancer and cancer treatments; necessary massage adaptations; and what will be required of them as members of a health care team. The core competencies this training program aims to impart, and the program developed to reach them, are outlined here. Specific training by a credible oncology team is required prior to any hands-on work with cancer patients.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 4","pages":"163-6"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2310/7200.2007.015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27904838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Echinacea purpurea.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 4","pages":"167-8"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27904839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nancy C Russell, Deanna M Hoelscher, Nicki Lowenstein
{"title":"Patients previously treated for lymphoma consume inadequate or excessive amounts of five key nutrients.","authors":"Nancy C Russell, Deanna M Hoelscher, Nicki Lowenstein","doi":"10.2310/7200.2007.009","DOIUrl":"https://doi.org/10.2310/7200.2007.009","url":null,"abstract":"<p><p>Adequate amounts of nutrients such as folate, vitamin A, iron, selenium and calcium are essential for general health including prevention of cancer. Yet, excess amounts of vitamin A, folate, and iron may also promote cancer. This study sought to determine whether adults who had completed initial treatments for B-cell lymphoma from 1 to 3 years earlier were consuming recommended amounts of these key nutrients and their interests in nutritional education. We surveyed 141 patients undergoing follow-up in the Lymphoma/Myeloma Clinic at The University of Texas M. D. Anderson Cancer Center using a validated food frequency questionnaire and supplemental questionnaire regarding nutritional interest. Nutrient intakes were estimated based on national databases of average content in foods and compared with recommended guidelines. One hundred forty-one participants returned complete questionnaires, but errors limited some nutrient estimates to 134 participants. Participants' mean age was 50, 55% were male, and 80% were non-Hispanic whites. Most participants (94%) were consuming either inadequate or excessive amounts of one or more of these key nutrients. Half of the participants were interested in receiving nutritional education. These findings are of concern because of their potential impact upon recovery and maintenance of general health and possibly cancer-related pathways after treatment.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 3","pages":"118-24"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26947711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brian D Lawenda, Donald E Smith, Lei Xu, Andrzej Niemierko, Joshua R Silverstein, Yves Boucher, Satoshi Kashiwagi, Kathryn D Held, Rakesh K Jain, Jay S Loeffler, David M Eisenberg, Jeffrey B Blumberg
{"title":"Do the dietary supplements epigallocatechin gallate or vitamin e cause a radiomodifying response on tumors in vivo? A pilot study with murine breast carcinoma.","authors":"Brian D Lawenda, Donald E Smith, Lei Xu, Andrzej Niemierko, Joshua R Silverstein, Yves Boucher, Satoshi Kashiwagi, Kathryn D Held, Rakesh K Jain, Jay S Loeffler, David M Eisenberg, Jeffrey B Blumberg","doi":"10.2310/7200.2006.033","DOIUrl":"10.2310/7200.2006.033","url":null,"abstract":"<p><p>The primary aim of this study was to evaluate a systematic and reproducible assay to examine the potential radiomodifying effects of vitamin E (VE) or epigallocatechin gallate (EGCG), antioxidants commonly consumed by cancer patients as dietary supplements, on tumor control. C3H mice were randomized to a control diet or to the control diet supplemented with VE or EGCG. A tumor control dose 50% (TCD(50)) assay was used to evaluate for a radiomodifying response in stage IV murine cancer (MCa-IV) tumors, implanted in the hindleg of mice, and allowed to grow to 8 mm before receiving a single dose of radiation. The effects of VE and EGCG on intratumoral angiogenesis and apoptosis were evaluated in a group of nonirradiated mice using immunohistochemical staining. Cell proliferation assays were conducted on MCa-IV tumors in vitro. EGCG slowed tumor growth rate by 10%. EGCG and VE slowed tumor regrowth by 24 to 25%. There were no significant differences in TCD(50) values between the groups (control = 73.9 Gy, VE = 77.2 Gy, EGCG = 76.4 Gy); however, normal tissues were protected from late radiation effects (autoamputations) in the VE group. VE and EGCG increased tumor cell apoptosis and decreased tumor cell proliferation but had no effect on microvessel density. In this pilot study, neither VE nor EGCG exerted a significant radiomodifying effect on the MCa-IV tumor. Nonetheless, the suggestion of a small degree of tumor radioprotection by these antioxidant compounds warrants further research. As supplementation with VE radioprotected normal tissue, additional studies on this putative benefit are recommended.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 1","pages":"11-7"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26561052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marie-Pierre Campeau, Réal Gaboriault, Martine Drapeau, Thu Van Nguyen, Isabelle Roy, Bernard Fortin, Mariette Marois, Phuc Félix Nguyen-Tân
{"title":"Impact of massage therapy on anxiety levels in patients undergoing radiation therapy: randomized controlled trial.","authors":"Marie-Pierre Campeau, Réal Gaboriault, Martine Drapeau, Thu Van Nguyen, Isabelle Roy, Bernard Fortin, Mariette Marois, Phuc Félix Nguyen-Tân","doi":"10.2310/7200.2007.018","DOIUrl":"10.2310/7200.2007.018","url":null,"abstract":"<p><p>Anxiety is a major issue in the cancer patient population. This randomized phase III trial evaluated the effects of massage therapy on anxiety levels in patients undergoing radiation therapy. Patients undergoing radiation therapy were randomly assigned to either 10 massage sessions or control sessions. Anxiety levels were evaluated throughout the course of treatment using both the visual analogue scale (VAS) and the State-Trait Anxiety Inventory (STAI). The immediate effect of massage therapy on anxiety scores was measured via pre- and postmassage VAS scores. The intermediate-term effect of massage was assessed through the VAS scores over the 10 sessions and STAI scores at the last session. The trial's primary outcome was the difference in intermediate-term anxiety scores, whereas the secondary outcome was the difference in immediate anxiety scores. Between January 2006 and June 2006, 100 patients were randomized. After their massage, the patients' immediate postmassage anxiety score according to the VAS was reduced by an average of 45% compared with their premassage score (p < .001). No impact of massage therapy on intermediate-term anxiety scores was observed. Both groups showed a similar decline in VAS anxiety scores from the first to the last session, that is, 15% and 19% in the massage therapy and control groups, respectively (p = .73). Furthermore, no difference was observed between the groups' respective state-anxiety scores after the 10 sessions. Massage therapy is associated with a significant, immediate decrease in anxiety scores. However, massage therapy appears to have no major impact on intermediate-term anxiety in patients undergoing radiation therapy.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 4","pages":"133-8"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27904834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anita H Ambs, Melissa F Miller, Ashley W Smith, Michael S Goldstein, An-Fu Hsiao, Rachel Ballard-Barbash
{"title":"Religious and spiritual practices and identification among individuals living with cancer and other chronic disease.","authors":"Anita H Ambs, Melissa F Miller, Ashley W Smith, Michael S Goldstein, An-Fu Hsiao, Rachel Ballard-Barbash","doi":"10.2310/7200.2007.003","DOIUrl":"https://doi.org/10.2310/7200.2007.003","url":null,"abstract":"<p><p>Religion and spirituality in the context of health care are poorly understood, particularly for individuals with chronic illness. Using data from the 2003 Complementary and Alternative Medicine supplement to the 2001 California Health Interview Survey, we examined whether cancer survivors (n = 1,777) and individuals with other chronic illnesses (n = 4,784) were either more likely to identify themselves as religious and spiritual or more likely to use religious and spiritual practices for health purposes than individuals with no disease (n = 2,342). We observed that cancer survivors and individuals with chronic illnesses were more likely than those with no disease to use religious and spiritual prayer and healing practices. Individuals with chronic diseases were not inherently more likely to identify themselves as religious than were healthy individuals and were only slightly more likely to identify themselves as spiritual. These findings indicate that individuals with cancer and other chronic illnesses may be using religious and spiritual practices as a way to cope with their illness. Future research should continue to examine whether and how religious and spiritual practices are used as complementary or alternative medicine, and health care professionals should ask their patients about such use.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 2","pages":"53-60"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26731350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical guide to herb-drug interactions in oncology.","authors":"K Simon Yeung, Jyothirmai Gubili","doi":"10.2310/7200.2007.008","DOIUrl":"https://doi.org/10.2310/7200.2007.008","url":null,"abstract":"<p><p>Cancer patients are increasingly using herbal supplements for relief of symptoms. However, there is a great potential for interactions with concurrent use of herbs and chemotherapy agents. Physicians should be aware of such interactions and encourage patients to discuss supplement use.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 3","pages":"113-7"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26947710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Which botanicals or other unconventional anticancer agents should we take to clinical trial?","authors":"Andrew J Vickers","doi":"10.2310/7200.2007.011","DOIUrl":"10.2310/7200.2007.011","url":null,"abstract":"<p><p>There is significant public and scientific interest as regards unconventional anticancer agents (complementary and alternative medicine [CAM] agents). This article describes five principles pertaining to the question of which CAM agents should be taken to clinical trial: (1) many CAM agents have been proposed as cancer treatments, far more than could possibly be studied in clinical trials; (2) claims by patients or practitioners are generally unhelpful in choosing which CAM agents to test; (3) laboratory studies can help determine which CAM agents to take to trial and with which cointerventions; (4) preliminary laboratory studies are essential to confirm safety before trials can be considered; and (5) the vast majority of anticancer CAM agents will be ineffective; our aim should be to discard agents from consideration as rapidly as possible.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"5 3","pages":"125-9"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590766/pdf/nihms79580.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26947712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}